HANSHOW
23.11.2022 08:01:41 CET | Business Wire | Press release
Jumbo, the second largest supermarket chain in the Netherlands which also has stores in Belgium, has announced an exclusive partnership with global retail solutions provider Hanshow to digitally transform its network of stores.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221117005660/en/
Hanshow's electronic shelf labels (ESLs) installed at Jumbo (Photo: Business Wire)
Jumbo was founded in 1921 and currently owns more than 700 stores in the Netherlands and Belgium. It is locally renowned for its wide range of selections and personalized attention to both customers and employees.
With the digital transformation of its business model, Jumbo is becoming one of the leading retailers in Europe. This is driven in part by the Jumbo Tech Campus which facilitates the innovation of Jumbo’s digital solutions and channels to connect its online and offline retail business while strengthening relationships with customers.
The collaboration with Hanshow is a crucial move in Jumbo's digitization strategy. To date, Hanshow’s solutions have been rolled out in over 250 stores. Soon Jumbo will have upgraded all 700 of its stores, with over 11 million Hanshow electronic price tags installed.
“The unique Jumbo formula revolves around a large assortment with the best service at low prices. Correct prices on the shelf and the ability to react quickly and efficiently to market developments are essential for this. The technology of Hanshow contributes to this.” Jumbo said.
At the heart of this digital transformation with Hanshow, the adoption of over 11 million electronic shelf labels (ESLs) will save time and energy across all Jumbo stores. Hundreds of thousands of paper price tags can be saved by this partnership each year, which is also in line with Jumbo’s abiding goal of sustainability. ESLs dramatically increase efficiency for retail operations such as inventory management and faster order picking with LED flashing functions. Additionally, ESLs improve the customer shopping experience with centralized price updates, error-free labeling, and enhanced store appearance.
Powering the systems management of this massive amount of ESL is made possible by adopting the Hanshow SaaS solution via Microsoft Azure. Benefits for Jumbo include reducing costs spent on infrastructure and servers, and if needed the Hanshow technical support team is capable of helping resolve technical issues much faster. Hanshow’s PriSmart ESL and IoT device management system also allows Jumbo to get the systems up and running sooner and the ability to manage and update its pricing network in a faster, more secure, and more accessible way.
“Hanshow solutions can drive sustainability, improve efficiency, eliminate waste, and create new opportunities for Jumbo stores,” notes Sally Liang, General Manager of Europe, Hanshow. “This is an exciting era for retail, and we’re proud to be partnering with a company like Jumbo that is committed to improving its customer experience and operational efficiency through digital retail transformation.”
The cooperation with Jumbo is a significant achievement for Hanshow’s international development. In the future, Hanshow looks forward to cooperating with global customers to further explore the paths of digital transformation, to further optimize digital store solutions, and to provide more comprehensive, intelligent, and efficient digital service upgrades.
About Hanshow
Hanshow is a global leader in developing and manufacturing electronic shelf labels and digital store solutions, offering global customers a series of world-class customized IoT touchpoints and digital store solutions that deliver customer-centric insights. Hanshow’s solutions are used by over 30,000 stores in more than 50 countries, helping retailers streamline operations, optimize pricing strategies, and offer consumers a more personalized experience. Learn more: www.hanshow.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221117005660/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Consortium Led by Axelspace Selected for Japan’s Space Strategy Fund Project “Technology to Enhance Capability of Next Generation Earth Observation Satellites”30.3.2026 01:35:00 CEST | Press release
~ Creating Climate Solutions and New Market Opportunities through Source-Specific CO2 Emission and Uptake Monitoring via Satellite Constellation and Aircraft ~ Axelspace Corporation, Meisei Electric Co., Ltd., ANA HOLDINGS INC., and JIJ Inc. are pleased to announce that their jointly proposed technology development project has been selected for Japan Aerospace Exploration Agency (JAXA)’s Space Strategy Fund under the theme “Technology to Enhance Capability of Next Generation Earth Observation Satellites.” This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260323044518/en/ Conceptual Diagram of the project. Under this Space Strategy Fund initiative, spectrometers will be newly developed and demonstrated in orbit. In the future, the project envisions the establishment of a satellite constellation capable of observations at different times of the day. Project Summary (Planned) Technology Development Theme: Technology to Enhance Cap
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom